Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | IL5 | P05113 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL16139563 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173264-A1 | NEW PHARMACEUTICAL COMPOSITIONS | CALLIDITAS THERAPEUTICS AB (SE) | 2024-05-30 | — | — | US | disclosed |
| US-20240122863-A1 | NEW PHARMACEUTICAL COMPOSITIONS | CALLIDITAS THERAPEUTICS AB (SE) | 2024-04-18 | — | — | US | disclosed |
| US-11896719-B2 | Pharmaceutical compositions | CALLIDITAS THERAPEUTICS AB (SE) | 2024-02-13 | — | — | US | disclosed |
| US-20240033225-A1 | PHARMACEUTICAL COMPOSITIONS | CALLIDITAS THERAPEUTICS AB (SE) | 2024-02-01 | — | — | US | disclosed |
| WO-2023042928-A1 | INHALABLE PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) | 한국유나이티드제약 주식회사 | 2023-03-23 | — | — | WO | disclosed |
| WO-2022035286-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION DISEASE-19 | 한국유나이티드제약 주식회사 | 2022-02-17 | — | — | WO | disclosed |
| EP-3513813-A1 | CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION | Astrazeneca (SE) | 2019-07-24 | — | — | EP | disclosed |
| US-9320746-B2 | Method for treating intestinal fibrosis | SIGMOID PHARMA LIMITED (IE) | 2016-04-26 | — | — | US | disclosed |
| US-20140234418-A1 | METHOD FOR TREATING INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2014-08-21 | — | — | US | disclosed |
| US-8491932-B2 | Compositions for the oral delivery of corticosteroids | ARCHIMEDES DEVELOPMENT LIMITED (GB) | 2013-07-23 | — | — | US | disclosed |
| US-8268240-B2 | Ciclesonide-containing sterile aqueous suspension | NYCOMED GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8182824-B2 | Ciclesonide-containing sterile aqueous suspension | NYCOMED GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20110104269-A1 | COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS | ARCHIMEDES DEVELOPMENT LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20100034696-A1 | Ciclesonide-containing sterile aqueous suspension | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20060166953-A1 | Ciclesonide-containing sterile aqueous suspension | COVIS PHARMA GMBH (CH) | 2006-07-27 | — | — | US | disclosed |
| US-20050288265-A1 | Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copd | MEDA PHARMA GMBH & CO. KG (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6239120-B1 | GLUCOCORTICOID HAVING A FIRST PASS METABOLISM IN THE LIVER OF AT LEAST 90% IN CONTACT WITH THE INTESTINAL WALL AREA. | PHARMALINK AB (SE) | 2001-05-29 | — | — | US | disclosed |
| US-5914122-A | SOLUTION WITH PH 6 OR LESS CONSISTS OF BUDESONIDE DISSOLVED IN A SOLVENT SELECTED FROM ETHANOL, ISOPROPANOL, PROPYLENE GLYCOL AND WATER, AN ETHYLENEDIAMINE TETRAACETIC ACID, SODIUM SALT STABILIZER; RACTAL ENEMA; STORAGE STABILITY | DR. FALK PHARMA GMBH (DE) | 1999-06-22 | — | — | US | disclosed |
| US-5053404-A | Antiinflammatory and antiasthmatic agents | RICHTER GEDEON VEGYESZETI GYAR R. T. (HU) | 1991-10-01 | — | — | US | disclosed |
| EP-0387090-A2 | Steroid derivatives,processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896719-B2 | Pharmaceutical compositions | PDCD2L, PGA5, NR3C2 | NR3C1 63/4885PGR 702/4885CYP3A4 300/4885 |
| US-20240033225-A1 | PHARMACEUTICAL COMPOSITIONS | PDCD2L, PGA5, NR3C2 | NR3C1 63/4885PGR 702/4885CYP3A4 300/4885 |
| US-20240122863-A1 | NEW PHARMACEUTICAL COMPOSITIONS | PDCD2L, PGA5, PDE12 | NR3C1 54/4885PGR 818/4885CYP3A4 445/4885 |
| US-20110104269-A1 | COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 623/4885CYP3A4 1480/4885 |
| US-20240173264-A1 | NEW PHARMACEUTICAL COMPOSITIONS | PDCD2L, PGA5, PDE12 | NR3C1 54/4885PGR 818/4885CYP3A4 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.